Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation Across the Spectrum of Chronic Airway Diseases - A Prospective Observational Study in Asthma and COPD

NCT07823842 is registered in ClinicalTrials.gov with Shanghai Pulmonary Hospital, Shanghai, China as lead sponsor.

NCT NCT07823842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07823842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation Across the Spectrum of Chronic Airway Diseases - A Prospective Observational Study in Asthma and COPD
Lead sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Phase
Observational
Overall status
Recruiting
Start date
July 30, 2026
Completion date
May 16, 2029
Enrollment
538 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma, copd (chronic obstructive pulmonary disease)